PointZero Group, a Dh120 billion ($33 billion) entity, is formed through a merger of three Abu Dhabi companies, focusing on ...

Are plant-based proteins like lentils, tofu, or quinoa just as effective as animal proteins like eggs, chicken, or dairy when ...

Merve Ceylan is a dietitian and health writer with four years of experience writing for companies in the nutrition and health industry. Nick Blackmer is a librarian, fact-checker, and researcher with ...

Read here for a detailed analysis of iShares Flexible Income Active ETF (BINC)’s investment outlook, growth prospects, risks, ...

Muscle cramps are sudden, involuntary contractions that can cause sharp, intense pain lasting from a few seconds to several minutes. They often strike during exercise, dehydration, or even while ...

The German government is set to raise its economic forecasts, bringing official projections into line with those of the country’s leading research institutes, people familiar with the matter said on ...

Shares of Canopy Growth Corp (NASDAQ:CGC) are trading lower Wednesday, pulling back from a sharp rally on Monday. The stock is seeing a downturn as initial excitement wanes following a social media ...

International Business Machines Corporation is rated hold with a $305 12-month price target, reflecting about 9% upside potential. IBM's strong FQ2 2025 results highlight double-digit bottom-line ...

CoreWeave is sitting on a massive backlog and remains capacity constrained as demand for artificial intelligence (AI) computing is outpacing supply. The company plans to significantly upgrade its ...

“America’s economic resurgence under President Trump continues: revised data show even stronger real GDP growth of 3.8 percent in Q2 2025 thanks to the Trump agenda of tax cuts, deregulation, tariffs, ...

Fit&Well is for everyone, regardless of age, gender and fitness levels. Our mission is simple: to help people achieve healthier, happier living. You’ll find a range of beginner-friendly workout ideas ...

Sept 23 (Reuters) - Scholar Rock (SRRK.O), opens new tab said on Tuesday the U.S. health regulator has declined to approve its drug for a rare neuromuscular disease citing issues at a third-party ...